Veradermics' VDPHL01 met its primary endpoint in a Phase II female pattern hair loss trial. The company plans a Phase III start in H2 2027.
Alpha Score of 67 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.
Veradermics (MANE) reported positive Phase II results for VDPHL01 in female pattern hair loss, with the drug meeting its primary endpoint of increased hair count at 24 weeks. The company presented the data in a slide deck published July 18.
The study enrolled 150 women with moderate to severe androgenetic alopecia. Patients receiving VDPHL01 showed a statistically significant improvement in target area hair count compared to placebo, Veradermics said. The company did not disclose the exact magnitude of the hair count increase in the slide deck.
Safety data showed no serious adverse events related to the drug. The most common side effects were mild scalp irritation and pruritus, consistent with earlier Phase I findings.
Veradermics plans to advance VDPHL01 into a Phase III program in the second half of 2027, the company said. The drug is a topical formulation of a proprietary small molecule designed to inhibit the androgen receptor in scalp follicles.
The stock rose 12% in after-hours trading following the release.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.